General Medical Devices

Biolife4d Corp

OPTIMI HEALTH CORP

HCW Biologics

FLAG SHIP ACQUISITION CORPORATION COM USD0.001 (SUB/RIGHT 31/03/2026)

Micware

Silexion Therapeutics

GCL Global

EMMIS ACQUISITION CORP. ORD USD0.0001 (S/R 12/09/2030)

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

RSLS

SAVU

SBIO

LABU

Restart Life Sciences Corp. announced that its subsidiary, Holy Crap Foods, has sold over 500,000 units from January 2023 to March 2026, indicating strong consumer adoption. The company aims to expand its market presence in Canada, the U.S., and the Caribbean, focusing on gut health and wellness products. CEO Steve Loutskou emphasized the importance of this milestone for brand recognition and ongoing growth. Restart Life is committed to developing a diversified wellness platform, integrating gut and brain health products, and enhancing distribution and brand awareness.

StockTitan

ReShape Lifesciences

ALPS Medical Breakthrough

SPDR S&P Health Equip

Direxion S&P Biotech Bull 3X

Global X HealthTech ETF

Direxion S&P Biotech Bear 3X

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

SPDR S&P Biotech

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption | NMLSF Stock News

ATNF

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

180 Life Sciences

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

BetterLife Pharma Launches $500,000 Private Placement to Advance LSD-Derived Neurology Drug

Tip Ranks

BetterLife Pharma Launches $500,000 Private Placement to Advance LSD-Derived Neurology Drug

HSPT

Horizon Space Acquisition II Corp. reported a net income of $1.81M for FY 2025, a significant increase from $143K in FY 2024, as per its 10-K summary. The company, which had no prior commercial operations, is transitioning to an operating public company following a merger with SL Bio Ltd. IPO proceeds of $69M are in trust for the acquisition. The company has secured short-term trust deposits to extend its combination period and is preparing for a Nasdaq listing after the merger's completion.

TradingView

Horizon Space Acquisition II

Mustang Bio

Invesco Nasdaq Biotechnology ETF

BioLife Solutions

Horizon Space Acquisition II Corp. FY 2025: Net income $1.81M — 10-K Summary

ARKG

ETNB

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

Ark Genomic Revolution ETF

89Bio

BioAge Labs

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

Restart Life Sciences has acquired Holy Crap Foods Inc., gaining 100% ownership of the functional cereal brand and its assets, which adds over $1 million in annual revenue. This acquisition allows Restart Life to become a revenue-producing organization and control a manufacturing facility in Gibsons, B.C. The company plans to leverage Holy Crap’s established customer base for expansion in the health and wellness sector. The latest analyst rating for Stuhini Exploration (TSE:NOVA) is a Hold with a price target of C$0.21, reflecting concerns over financial performance despite some positive technical indicators.

180 LIFE SCIENCES CORP C/WTS 07/11/2025(TO PUR COM)

Restart Life Sciences Becomes Revenue Producer With Holy Crap Foods Acquisition

Biolife4d Corp(SAVU.US)

Restart Life Sciences' Wholly Owned Subsidiary Holy Crap Foods Reports over 500,000 Units Sold, Highlighting Strong Consumer Adoption | NMLSF Stock News

Restart Life Sciences Provides Performance and Revenue Trend Update on Newly Acquired Superseed Cereals and Oatmeal Brand Portfolio | NMLSF Stock News

BetterLife Pharma Launches $500,000 Private Placement to Advance LSD-Derived Neurology Drug

Horizon Space Acquisition II Corp. FY 2025: Net income $1.81M — 10-K Summary

4basebio Leases New Cambridge Facility to Scale Synthetic DNA Manufacturing

Restart Life Sciences Becomes Revenue Producer With Holy Crap Foods Acquisition